| 3.05 -0.01 (-0.33%) | 09-13 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.97 | 1-year : | 4.63 |
| Resists | First : | 3.39 | Second : | 3.97 |
| Pivot price | 3.03  |
|||
| Supports | First : | 2.92 | Second : | 2.62 |
| MAs | MA(5) : | 3.01 |
MA(20) : | 2.97 |
| MA(100) : | 3.08 |
MA(250) : | 2.27 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 50.4 |
D(3) : | 48.4 |
| RSI | RSI(14): 51.3  |
|||
| 52-week | High : | 4.15 | Low : | 0.94 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ NUVB ] has closed below upper band by 47.2%. Bollinger Bands are 32% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 3.14 - 3.16 | 3.16 - 3.17 |
| Low: | 2.98 - 3.01 | 3.01 - 3.03 |
| Close: | 3.02 - 3.05 | 3.05 - 3.08 |
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation; NUV-569, a differentiated oral small molecule selective inhibitor of the Wee1 kinase for DNA damage repair; NUV-1182, an adenosine receptor inhibitor; and drug-drug conjugate (DDC) platform that focuses on targeting an inhibitor of poly ADP ribose polymerase (PARP) to anti-cancer warheads of existing drugs, as well as PARP inhibitor to address ER+ breast and ovarian cancer. The company was formerly known as RePharmation Inc. and changed its name to Nuvation Bio Inc. in April 2019. Nuvation Bio Inc. was founded in 2018 and is headquartered in New York, New York.
Wed, 11 Sep 2024
Owning 41% shares,institutional owners seem interested in Nuvation Bio Inc. (NYSE:NUVB), - Simply Wall St
Tue, 10 Sep 2024
Nuvation Bio (NYSE:NUVB) Trading Up 8.6% - MarketBeat
Mon, 09 Sep 2024
Nuvation Bio to Present at the Cantor Global Healthcare Conference - Business Wire
Thu, 22 Aug 2024
With 47% stake, Nuvation Bio Inc. (NYSE:NUVB) seems to have captured institutional investors' interest - Yahoo Finance
Thu, 08 Aug 2024
Nuvation Bio: Continuing To Justify A Buy Thesis With Catalysts In 2024 (NYSE:NUVB) - Seeking Alpha
Fri, 12 Jul 2024
We Think Nuvation Bio (NYSE:NUVB) Can Easily Afford To Drive Business Growth - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 248 (M) |
| Held by Insiders | 1.5045e+008 (%) |
| Held by Institutions | 27.6 (%) |
| Shares Short | 14,280 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -5.3734e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -32 % |
| Return on Assets (ttm) | 779.4 % |
| Return on Equity (ttm) | -54.4 % |
| Qtrly Rev. Growth | 1.44e+006 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -63.08 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -2.3 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -84 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.05 |
| Price to Cash Flow | 4.14 |
| Dividend | 0 |
| Forward Dividend | 1.65e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|